State Street Corp Apellis Pharmaceuticals, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 4,040,861 shares of APLS stock, worth $134 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,040,861

Previous 4,146,694 2.55%

Holding current value

$134 Million

Previous $159 Million 26.74%

% of portfolio

0.0%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $3.05 Million - $4.36 Million	-105,833 Reduced 2.55%	4,040,861 $117 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $47.1 Million - $73.9 Million	1,237,166 Added 42.52%	4,146,694 $159 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $326,468 - $427,138	-5,894 Reduced 0.2%	2,909,528 $171 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $12 Million - $20.9 Million	-322,692 Reduced 9.97%	2,915,422 $175 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $22.6 Million - $85.2 Million	955,029 Added 41.83%	3,238,114 $123 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $53.4 Million - $65 Million	-696,777 Reduced 23.38%	2,283,085 $208 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $22.9 Million - $32.9 Million	-492,052 Reduced 14.17%	2,979,862 $197 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $22.3 Million - $31.4 Million	514,641 Added 17.4%	3,471,914 $180 Million
Q3 2022 Nov 15, 2022	SELL	$44.76 - $69.66 $24.2 Million - $37.6 Million	-539,652 Reduced 15.43%	2,957,273 $202 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $20.7 Million - $35 Million	590,469 Added 20.32%	3,496,925 $158 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $6.63 Million - $10.1 Million	187,088 Added 6.88%	2,906,456 $148 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $3.28 Million - $5.25 Million	-106,827 Reduced 3.78%	2,719,368 $129 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $27.6 Million - $61.4 Million	879,227 Added 45.16%	2,826,195 $93.2 Million
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $10.3 Million - $16.3 Million	-251,605 Reduced 11.44%	1,946,968 $123 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $9.47 Million - $13.3 Million	-232,180 Reduced 9.55%	2,198,573 $94.3 Million
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $13.3 Million - $24.8 Million	-433,406 Reduced 15.13%	2,430,753 $139 Million
Q3 2020 Nov 10, 2020	SELL	$25.89 - $33.65 $2.14 Million - $2.78 Million	-82,655 Reduced 2.8%	2,864,159 $86.4 Million
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $11.1 Million - $17.2 Million	448,050 Added 17.93%	2,946,814 $96.2 Million
Q1 2020 May 11, 2020	BUY	$17.91 - $44.33 $44.8 Million - $111 Million	2,498,764 New	2,498,764 $66.9 Million

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Apellis Pharmaceuticals, Inc. Transaction History